https://vitasmlab.net

ALZHMARK

Alzheimer's Disease Targeted Library

Alzheimer's disease is a progressive neurodegenerative disorder and the leading cause of dementia, affecting millions worldwide. It is characterized by amyloid beta plaques and tau tangles, which drive neuronal loss and cognitive decline. Current therapies offer only minor symptomatic relief without modifying disease progression, leaving a vast unmet need for effective treatments. The rising global burden of Alzheimer's—economically, socially, and in human suffering—underscores the urgent necessity for novel small molecule drugs. Disease-modifying small molecules, especially those capable of acting on multiple pathological nodes, hold the promise of slowing or halting neurodegeneration. Developing these agents is not merely a scientific goal; it is a public health imperative to preserve cognitive function, maintain quality of life, and ultimately find a cure for this devastating condition.



Example Targets:

GSK-3β Tau Aggregation

Cholinesterase Alpha-Synuclein Aggregation

APP



STK191863



STK510793



STL390412

Alzheimer's Disease Targeted Library (ALZHMARK) consists of compounds which were selected based on similarity to known effectors of Alzheimer's pathological processes. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. The library prioritizes structural diversity and drug-like properties, including BBB score of 2 or higher, while filtering out compounds with undesirable motifs. This library has 2806 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at
irina@vitasmlab.biz
Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!
Empowering Your Research, One Molecule at a Time.